logowsbdaily | Wed, 10 Aug 2022 07:32:32 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

CVRx, Inc.
(CVRX)

CVRx, Inc.
9201 West Broadway Avenue
Suite 650
Minneapolis, MN 55445
United States
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe,... Read More

Summary & Charts

Price$ 8.83+1.28 (+16.95%)
Day's Range$ 7.75 - 9.19 
Previous Close$ 7.55
Market Cap$ 181.69M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqGS
IndustryMedical Devices
SectorHealthcare
Volume246.82K
Avg. Volume (20 day)57.25K
Rel. Volume (20 day)4.31
Rel. Volume (3 month)2.24
RatingB+Neutral
DCFN/AStrong Buy
Debt/Equity5.56 %Neutral
ROE-148.64 %Neutral
ROA-30.78 %Neutral
P/E-4.06 %Strong Sell
P/B1.32 %Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Jul 29, 2022$ 7.94$ 9.19$ 7.75$ 8.83+1.28246,8224.312.24
Jul 28, 2022$ 7.27$ 7.64$ 7.07$ 7.55+0.3234,5910.730.27
Jul 27, 2022$ 7.44$ 7.44$ 7.08$ 7.23-0.0735,4060.720.26
Jul 26, 2022$ 7.29$ 7.34$ 7.05$ 7.30-0.0932,6450.660.24
Jul 25, 2022$ 7.18$ 7.40$ 7.18$ 7.39+0.1620,6390.380.15
Jul 22, 2022$ 7.75$ 7.75$ 7.11$ 7.23-0.4741,8740.380.30
Jul 21, 2022$ 7.29$ 7.70$ 7.10$ 7.70+0.4252,3000.450.37
Jul 20, 2022$ 7.07$ 7.35$ 7.07$ 7.28+0.2832,0000.270.23
Jul 19, 2022$ 7.15$ 7.20$ 6.90$ 7.00-0.0673,9000.600.52
Jul 18, 2022$ 7.23$ 7.57$ 7.02$ 7.06+0.28113,3000.850.80
Jul 15, 2022$ 6.86$ 6.96$ 6.66$ 6.78+0.0656,0000.400.40
Jul 14, 2022$ 6.34$ 6.78$ 6.07$ 6.72+0.3442,6000.300.30
Jul 13, 2022$ 6.30$ 6.48$ 6.30$ 6.3862,4000.440.44
Jul 12, 2022$ 6.53$ 6.53$ 6.35$ 6.38-0.0831,3000.220.22
Jul 11, 2022$ 6.70$ 6.75$ 6.42$ 6.46-0.2421,4000.150.15
Jul 08, 2022$ 6.84$ 6.95$ 6.66$ 6.70-0.0746,0000.300.31
Jul 07, 2022$ 6.45$ 6.82$ 6.38$ 6.77+0.4054,8000.350.37
Jul 06, 2022$ 6.53$ 6.62$ 6.30$ 6.37-0.1225,7000.160.17
Jul 05, 2022$ 5.99$ 6.71$ 5.99$ 6.49+0.3774,2000.450.49
Jul 01, 2022$ 6.06$ 6.38$ 5.88$ 6.12+0.1147,2000.290.31

News

The latest news about CVRx, Inc. (CVRX).

Seeking Alpha | 2022-07-29 15:07:03
CVRx, Inc. (NASDAQ:CVRX ) Q2 2022 Earnings Conference Call July 28, 2022 5:30 PM ET Company Representatives Nadim Yared - President, Chief Executive Officer Jared Oasheim - Chief Financial Officer Mike Vallie - Westwicke, ICR Company Conference Call Participants Matthew O'Brien - Piper Sandal Margaret Kaczor - William Blair Alex Nowak - Craig-Hallum William Plovanic - Canaccord Operator Good day and thank you for standing by. Welcome to the CVRx Second Quarter 2022 Earnings Conference Call.
GlobeNewsWire | 2022-07-29 08:30:00
MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022. The Company is scheduled to present at 8:30 am Eastern Time the same day via webcast.
Zacks Investment Research | 2022-07-28 19:30:36
CVRx (CVRX) delivered earnings and revenue surprises of 0% and 6.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire | 2022-07-14 16:30:00
MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2022 financial and operating results after market close on Thursday, July 28th, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.
Zacks Investment Research | 2022-06-27 10:46:00
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewsWire | 2022-05-23 16:30:00
MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022. The Company is scheduled to present at 3:20 pm Central Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 90 days. About CVRx, Inc. CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-07-28AMC-0.54-0.54--4.7M----
2022-05-17AMC-0.49----4.1M4.1M-0.35%
2022-04-25AMC-0.49-0.49--4.1M4.1M-0.35%
2022-02-15AMC-0.43-0.5220.93%4.1M3.7M-10.57%
2021-11-04AMC-0.38-0.3021.06%3.3M3.4M3.5%
2021-08-04AMC-21.27-48.48127.92%2.2M3.1M44.67%

Top Discussions

These are the top discussions over the last 24-hours that mention the CVRX stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.